As an important medical drug for the treatment of pulmonary hypertension, Ambrisentan requires patients and medical staff to strictly abide by certain precautions during its use. This article will elaborate on the precautions of Ambrisentan in detail, aiming to provide necessary reference and guidance for patients and medical staff to ensure that the drug can achieve the best therapeutic effect and minimize potential risks.

Precautions for Ambrisentan (Endobloc)

Embryo-fetal toxicity

Ambrisentan may cause harm to the fetus when taken during pregnancy, and pregnant women are prohibited from using it. For women of reproductive potential, exclude pregnancy before starting treatment, ensure the use of acceptable contraceptive methods, and perform monthly pregnancy tests.

Risk Evaluation and Mitigation Plan (REMS)

All women, regardless of reproductive potential, must participate in the Ambrisentan REMS before starting Ambrisentan. Male patients are not included in the REMS. Women of reproductive potential must comply with pregnancy testing and contraception requirements.

Fluid retention

If clinically significant fluid retention occurs, with or without weight gain, further evaluation should be performed to determine the cause, such as the use of Ambrisentan or underlying heart failure, and whether specific treatment or discontinuation of Ambrisentan therapy is required.

Pulmonary edema with pulmonary veno-occlusive disease (PVOD)

If a patient develops acute pulmonary edema when starting treatment with a vasodilator such as Ambrisentan, the possibility of PVOD should be considered, and if confirmed, Ambrisentan tablets should be discontinued.

Decreased sperm count

Ambrisentan may have adverse effects on spermatogenesis. Patients are advised to consult their physician about the potential effects of Ambrisentan on fertility.

Blood changes

Measure hemoglobin one month before starting Ambrisentan and periodically thereafter. Ambrisentan tablets are not recommended for patients with clinically significant anemia at the start of treatment. If a clinically significant decrease in hemoglobin is observed and other causes have been excluded, consider discontinuing Ambrisentan tablets.

Through the scientific and rational use of Ambrisentan, we believe that we can effectively relieve related symptoms, improve the quality of life, and protect health. Let us work together to contribute to the patient's road to recovery.